4D Molecular Therapeutics, Inc.

NASDAQ:FDMT

Biotechnology

Healthcare
$10.46 +1.70%

+$0.16 today

Market cap
$577.85M
Beta
2.76
P/E (TTM)
-4.0
EPS (TTM)
-$2.36
52W Low $3.68High $12.34

Volume 0.68M

Average 0.77M

FDMT Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

4D Molecular Therapeutics, Inc.NASDAQ: FDMT

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization growth accelerates

Q1 FY2026 depreciation & amortization of $2.06M rose 17.2% year over year, ahead of the +0.4% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 3.8% from the prior quarter. Over 3 fiscal years it compounded at +46.9% a year.

Context

  • Depreciation & amortization amounted to 8.9% of revenue in FY2025, down 18112.7 pp from a year earlier.
  • Depreciation & amortization increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +17.2% holds above the trailing-twelve-month pace of +0.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.06M+3.8% QoQ
Last fiscal yearDec 2025
$7.63M+13.7% YoY
LTMMar 2026
$6.46M+0.4% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+17.2%——
1 year+13.7%——
3-year CAGR+46.9%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
7.63M USD
Year-over-year change
+13.7%
4-year CAGR
+49.6%

Depreciation & Amortization vs competitors

How FDMT compares with its peers on the latest reported figures

  • FDMT's LTM Mar 2026 depreciation & amortization of $6.46M is the 4th highest of the 8 companies compared; the peer median is $3.62M.
  • Its year-over-year change of +0.4% is the 4th highest of 8, against a peer median of -3.0%.
  • Depreciation & amortization amounts to 7.3% of revenue for FDMT, versus a peer median of 24.9%.
FDMT Competitors Peer median
Depreciation & Amortization for FDMT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RGNXREGENXBIO Inc.LTM Mar 2026$15.52M -3.0%+6.5%17.7%
QUREuniQure N.V.LTM Mar 2026$13.19M -9.3%+20.0%72.9%
MGTXMeiraGTx Holdings plcLTM Mar 2026$12.82M +2.6%+13.6%16.1%
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026$6.46M +0.4%+46.9%7.3%
ABEOAbeona Therapeutics Inc.LTM Mar 2026$3.62M +20.6%-8.0%24.9%
OCGNOcugen, Inc.LTM Mar 2026$2.47M -8.6%+70.7%55.3%
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 2026$2.12M +4.8%+22.0%—
SLDBSolid Biosciences Inc.LTM Mar 2026$1.62M -35.9%-12.1%—
Peer median (excluding FDMT) $3.62M-3.0%+13.6%24.9%

Competitors are the stored peer set for FDMT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue18.04M3.13M20.72M37K85.21M
Cost of Revenue61.36M80.25M97.1M141.3M7.63M
Gross Profit(43.32M)(77.12M)(76.37M)(141.26M)77.58M
Gross Margin-240.2%-2464.8%-368.5%-381789.2%91.1%
Research & Development61.36M80.25M97.1M141.3M195.7M
Selling, General & Admin28.01M32.91M36.49M46.58M49.06M
Operating Expenses28.01M32.91M36.49M46.58M237.13M
Depreciation & Amortization1.52M2.4M4.2M6.71M7.63M
EBITDA(69.79M)(105.09M)(96.63M)(154.16M)(132.48M)
EBITDA Margin-386.9%-3358.6%-466.3%-416656.8%-155.5%
Operating Income(71.33M)(110.03M)(112.87M)(187.84M)(159.55M)
Operating Margin-395.5%-3516.5%-544.6%-507678.4%-187.2%
Interest Income137K2.57M12.21M27.05M19.48M
Interest Expense00000
Other Income / Expenses16K2.54M12.03M26.97M19.44M
Income Before Tax(71.32M)(107.49M)(100.84M)(160.87M)(140.11M)
Pre-Tax Margin-395.4%-3435.4%-486.6%-434778.4%-164.4%
Income Tax Expense00000
Net Income(71.32M)(107.49M)(100.84M)(160.87M)(140.11M)
Net Margin-395.4%-3435.4%-486.6%-434778.4%-164.4%
EPS (Basic)(2.46)(3.12)(2.58)(2.98)(2.42)
EPS (Diluted)(2.46)(3.12)(2.58)(2.98)(2.42)
Weighted Avg Shares27.73M32.35M39.13M53.94M57.93M
Weighted Avg Shares (Diluted)27.73M32.35M39.13M53.94M57.93M

4D Molecular Therapeutics, Inc.

NASDAQ:FDMT

Intrinsic Alpha fair value

Locked

Current Price

$10.46

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.